Bariatrics
Return to Library
Study results from K. Ukinc and colleagues update understanding of obesity and diabetes
2009 AUG 3 - (NewsRx.com) -- According to recent research from Canakkale, Turkey, "Type 2 diabetes mellitus is the leading cause of macrovascular diseases and related death. Additionally, diabetes mellitus is frequently complicated by other cardiovascular risk factors, such as hypercholesterolemia, hypertension, obesity, hypercoagulability, and inflammation." "We wanted to evaluate and compare the effects of treating with a one-year course of atorvastatin or simvastatin on inflammatory markers such as high sensitive C-reactive protein (hsCRP), fibrinogen, and ferritin in uncontrolled type 2 diabetic patients. Also, we planned to investigate the correlation between inflammatory markers and metabolic parameters. Fifty type 2 diabetic patients (30 women, 20 men; mean age: 49.9 +/- A 8.5 years) were enrolled into the study. Twenty healthy subjects, matched on body mass index and age, were also included in the study as a control group. Diabetic patients were divided into two groups and received simvastatin or atorvastatin (Group S and A, respectively). After 1 year of statin treatment (Group A), there were significant decreases in total cholesterol (217.3 +/- A 46.5-173.8 +/- A 37.2 mg/dl; P< 0.0001), LDL-cholesterol (146.7 +/- A 50.3-102.3 +/- A 31.1 mg/dl, P< 0.0001), hsCRP (0.88 +/- A 0.62-0.35 +/- A 0.18 mg/dl, P< 0.0001), fibrinogen (258.2 +/- A 16.9-215.5 +/- A 10.6 mg/l; P< 0.0001), and ferritin (118.2 +/- A 73.9-81.2 +/- A 72.5 ng/ml, P< 0.0001) levels compared to basal values. In the S group, there were significant decreases in total cholesterol (224.4 +/- A 61.2-175.0 +/- A 47.8 mg/dl; P< 0.0001), LDL-cholesterol (140.9 +/- A 56.7-110.9 +/- A 42.2 mg/dl, P< 0.0001), hsCRP (0.98 +/- A 1.3-0.46 +/- A 0.25 mg/dl, P< 0.0001), fibrinogen (265.7 +/- A 26.8-222.1 +/- A 20.6 mg/l; P< 0.0001), and ferritin (136.7 +/- A 101.1-85.6 +/- A 32.1 ng/ml, P< 0.0001) levels compared to basal values. At the end of the study, a dagger hsCRP, a dagger fibrinogen, and a dagger ferritin levels were correlated with a dagger LDL (r = 0.42; P = 0.005, with a dagger hsCRP), (r = 0.40; P = 0.008, with a dagger fibrinogen), (r = 0.46; P = 0.002, with a dagger ferritin) and a dagger HDL (r = -0.50; P< 0.0001, with a dagger hsCRP), (r = -0.32; p = 0.042, with a dagger fibrinogen), (r = -0.48; P< 0.0001, with a dagger ferritin) cholesterol levels," wrote K. Ukinc and colleagues. The researchers concluded: "Atorvastatin and simvastatin treatments were found to be effective for the control of hypercholesterolemia and resulted in a significant decrease in acute phase reactants in uncontrolled type 2 diabetic patients." Ukinc and colleagues published their study in Endocrine (Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine, 2009;35(3):380-388). For additional information, contact K. Ukinc, Canakkale Onsekiz Mart University, Faculty Medical, TR-17020 Canakkale, Turkey. Publisher contact information for the journal Endocrine is: Humana Press Inc., 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. Keywords: Turkey, Canakkale, Angiology, Atorvastatin, Bariatrics, Biotechnology, C Reactive Protein, Cardiology, Cardiovascular, Cardiovascular Risk, Clinical Trial Research, Diabetes Mellitus, Drugs, Endocrine, Endocrinology, Hypercholesterolemia, Hypertension, Inflammation, Obesity, Obesity and Diabetes, Pharmaceuticals, Proteomics, Simvastatin, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
